source
- Novo to pay up to $2.6 billion for rights to Hengrui’s experimental weekly obesity pillNovo Pharmaceuticals has signed a licensing agreement with China's Hengrui Pharma to acquire an experimental oral weight‑loss drug that is administered once a week. Under the deal, Novo could pay…
- Novo Nordisk licenses weekly oral obesity peptide from Hengrui in up to $2.6 billion dealNovo Nordisk has signed a licensing agreement with China's Hengrui Pharma for a once‑weekly oral peptide, HRS‑1596, aimed at obesity and other metabolic conditions. Novo will pay $300 million upfr…